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Abstract
Background: Patients with rheumatoid arthritis (RA), including those treated with biologics, are at increased risk of
some vaccine-preventable infections. We evaluated the antibody response to standard 23-valent pneumococcal
polysaccharide vaccine (PPSV23) and the 2011–2012 trivalent seasonal influenza vaccine in adults with RA receiving
subcutaneous (SC) abatacept and background disease-modifying anti-rheumatic drugs (DMARDs).
Methods: Two multicenter, open-label sub-studies enrolled patients from the ACQUIRE (pneumococcal and influenza)
and ATTUNE (pneumococcal) studies at any point during their SC abatacept treatment cycle following
completion of ≥3 months’ SC abatacept. All patients received fixed-dose abatacept 125 mg/week with
background DMARDs. A pre-vaccination blood sample was taken, and after 28 ± 3 days a final post-vaccination
sample was collected. The primary endpoint was the proportion of patients achieving an immunologic
response to the vaccine at Day 28 among patients without a protective antibody level to the vaccine antigens
at baseline (pneumococcal: defined as ≥2-fold increase in post-vaccination titers to ≥3 of 5 antigens and
protective antibody level of ≥1.6 μg/mL to ≥3 of 5 antigens; influenza: defined as ≥4-fold increase in
post-vaccination titers to ≥2 of 3 antigens and protective antibody level of ≥1:40 to ≥2 of 3 antigens). Safety
and tolerability were evaluated throughout the sub-studies.
Results: Pre- and post-vaccination titers were available for 113/125 and 186/191 enrolled patients receiving the
PPSV23 and influenza vaccine, respectively. Among vaccinated patients, 47/113 pneumococcal and 121/186
influenza patients were without protective antibody levels at baseline. Among patients with available data, 73.
9 % (34/46) and 61.3 % (73/119) met the primary endpoint and achieved an immunologic response to PPSV23
or influenza vaccine, respectively. In patients with pre- and post-vaccination data available, 83.9 % in the
pneumococcal study demonstrated protective antibody levels with PPSV23 (titer ≥1.6 μg/mL to ≥3 of 5
antigens), and 81.2 % in the influenza study achieved protective antibody levels (titer ≥1:40 to ≥2 of 3
antigens) at Day 28 post-vaccination. Vaccines were well tolerated with SC abatacept with background
DMARDs.
Conclusions: In these sub-studies, patients with RA receiving SC abatacept and background DMARDs were
able to mount an appropriate immune response to pneumococcal and influenza vaccines.
Trial registration: NCT00559585 (registered 15 November 2007) and NCT00663702 (registered 18 April 2008).
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Background
Patients with rheumatoid arthritis (RA), including those
being treated with biologics, are at an increased risk of
some vaccine-preventable infections [1–4]. Two of the
most frequent infections that have resulted in increased
hospitalizations and/or death among patients with RA
are caused by Streptococcus pneumoniae and Haemophi-
lus influenzae, for which vaccinations exist [1]. Thus,
implementation of a vaccination strategy is needed for
daily clinical practice [4].
Patients with RA may need to receive immunizations
following initiation of biologic therapy if their
immunization status is not up to date (e.g. pneumococ-
cal vaccine, annual seasonal flu vaccine) [4–6]. Given
concerns regarding infection in patients receiving bio-
logic therapy, treatment guidelines recommend routine
use of pneumococcal and influenza vaccines in immuno-
compromised patients [7]. However, despite recommen-
dations, the use of vaccines (e.g. pneumococcal and
non-live influenza vaccines) is low in patients with RA
compared with the general population [8–10]. This is
partly due to uncertainty regarding the safety and effi-
cacy of vaccines in patients treated with immunomodu-
latory therapies [4, 11].
Abatacept is approved for the treatment of moderate-
to-severe RA, as an intravenous (IV) weight-tiered dos-
ing regimen, and as a subcutaneous (SC) fixed dose.
Abatacept is a soluble fusion protein that selectively
modulates the CD28:CD80/86 co-stimulatory signal re-
quired for full T-cell activation [12–15]. Long-term
treatment with SC and IV abatacept is associated with
low incidences of serious infections and is well tolerated
[16, 17]. A previous study in healthy volunteers sug-
gested that, although responses may be blunted, IV aba-
tacept does not impair the ability to mount an
appropriate immune response to the tetanus toxoid or
23-valent pneumococcal vaccines [18]. In a sub-study of
the ARRIVE (Abatacept Researched in Rheumatoid arth-
ritis patients with an Inadequate anti-TNF response to
Validate Effectiveness) trial, 81 and 75 % of abatacept-
treated patients with active RA responded to at least one
pneumococcal or influenza strain, respectively, demon-
strating that patients treated with abatacept are able to
mount an immune response to pneumococcal or influ-
enza vaccination [19, 20]. In addition, in patients with
psoriasis treated with IV abatacept, responses to two T
cell-dependent antigens to which the patients had not
been previously exposed (neoantigens: PhiX174 and key-
hole limpet hemocyanin) were reduced, but not com-
pletely blocked (Additional file 1: Table S1) [21]. In this
report, we describe results from influenza and pneumo-
coccal vaccination sub-studies that were performed in
patients with RA receiving SC abatacept. These results
confirm the IV formulation results in a larger subset of
patients, and thereby inform vaccination and treatment
decisions for patients with RA who are considering
treatment with or currently receiving abatacept.
Methods
Study design
Two multicenter, open-label sub-studies of the Phase
IIIb ACQUIRE (Abatacept Comparison of sub[QU]cuta-
neous versus intravenous in Inadequate Responders to
methotrexatE) and ATTUNE (Abatacept in subjecTs
who swiTch from intravenoUs to subcutaNeous thErapy)
studies evaluated response to the 23-valent pneumococ-
cal polysaccharide vaccine (PPSV23) and seasonal influ-
enza vaccine for enrolled patients. ACQUIRE was a
double-blind, double-dummy, 6-month study in 1457
patients with active RA and an inadequate response to
methotrexate (MTX) [22]. ATTUNE was an open-label,
single-arm, 12-month study in 123 patients with active
RA that was previously refractory to either MTX or
anti-tumor necrosis factor drugs and who switched to
SC abatacept following ≥4 years of IV abatacept in the
AIM (Abatacept in Inadequate responders to Methotrex-
ate) or ATTAIN (Abatacept Trial in Treatment of Anti-
TNF INadequate responders) clinical trials [23]. During
ACQUIRE and ATTUNE, SC abatacept was given at a
fixed dose of 125 mg/week, with background disease-
modifying anti-rheumatic drugs (DMARDs). SC
abatacept-treated patients from ACQUIRE or ATTUNE
were enrolled in the vaccination sub-study at any point
during their SC abatacept treatment cycle following
completion of ≥3 months of SC abatacept. Exclusion cri-
teria for both sub-studies included: patients with a his-
tory of known allergy or allergy to egg, chicken proteins,
neomycin, formaldehyde, or octoxinol-9; and patients
who had received a pneumococcal vaccination within
5 years or an influenza vaccination within 6 months for
each sub-study, respectively, based on the rate of decline
of response [24, 25]. The vaccination sub-studies con-
sisted of an initial visit for pre-vaccination blood sample
collection and vaccine administration, follow-up of 28 ±
3 days [26–28], and a final visit for post-vaccination
blood sample collection. Antibody response to the
pneumococcal vaccine was evaluated for patients in AC-
QUIRE and ATTUNE; response to the influenza vaccine
was evaluated only in ACQUIRE.
Assessments
For both the pneumococcal and influenza vaccination
sub-studies, the primary endpoint was the proportion of
patients without a protective antibody level to the vac-
cine antigens at baseline who achieved an immunologic
response (defined below) to the vaccine at Day 28. Ex-
ploratory endpoints included immunologic responses in
patients with protective vaccine antibodies at baseline,
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and the proportion of patients achieving post-
vaccination protective antibody levels. Efficacy assess-
ments were based on antibody response to the standard
PPSV23 or trivalent seasonal influenza virus vaccine in
adult patients who were on a stable dose of SC abatacept
and background DMARD therapy. Antibody titers for
the pneumococcal vaccine were evaluated using a stand-
ard enzyme-linked immunosorbent assay for the follow-
ing five antigens: 9V, 14, 18C, 19F, and 23F (antigens
previously investigated during pneumococcal vaccine
studies [29–31]). For the influenza vaccine, antibody ti-
ters were evaluated for the following three antigens:
H1N1 (A/California), A/H3N2 (A/Victoria), and B/Bris-
bane. The primary pre-specified efficacy endpoint for the
pneumococcal sub-study was the proportion of patients
achieving an immunologic response, defined as a ≥2-fold
increase in post-vaccination titers to ≥3 of 5 antigens (9V,
14, 18C, 19F, and 23F) [18, 21, 23, 29, 30, 32] at Day 28, in
patients without a protective antibody level to these
antigens at baseline. A protective antibody response to the
pneumococcal antigens was defined as a titer of ≥1.6 μg/mL
to ≥3 to 5 antigens [19, 21, 23, 25, 30, 31]. A conservative
immunologic response to the pneumococcal antigens (with
respect to the standard definition used for the primary end-
point) was defined as a ≥4-fold increase in post-vaccination
titers to ≥3 of 5 antigens (9V, 14, 18C, 19F, and 23F). The
primary efficacy endpoint specified in the influenza sub-
study was the proportion of patients achieving an im-
munologic response, defined as a ≥4-fold increase in
post-vaccination titers to ≥2 of 3 evaluated 2011–
2012 influenza antigens (A/H1N1, A/H3N2, and B/
Brisbane) [20, 21, 23, 30, 33, 34] at Day 28, in
patients without a protective antibody level to these
antigens at baseline. A protective antibody response
to the influenza antigens was defined as a titer of
≥1:40 to ≥2 of 3 influenza antigens [21, 23, 30, 31, 34]. A
conservative immunologic response to influenza was not
defined. Antibody titers for the influenza vaccine response
were evaluated using a hemagglutination inhibition assay.
Safety and tolerability were assessed throughout the
sub-studies. The following adverse event (AE) assess-
ments were performed: all AEs including clinical and
laboratory categorized by severity, serious AEs (SAEs),
and AEs of special interest (i.e. infections, autoimmune
disorders, injection reactions to the vaccine). Safety as-
sessments also included discontinuations due to AEs,
and AEs specific to the pneumococcal or influenza vac-
cine. AEs and SAEs were classified using the Medical
Dictionary for Regulatory Activities.
Statistical analyses
Patients with >42 days between the pre- and post-
vaccination sample dates were excluded from all ana-
lyses. A logistic regression model (odds ratios [OR] and
95 % confidence intervals [CIs]) was performed to evalu-
ate the relationship of baseline factors (i.e. protective
antibody level, MTX dose, concomitant steroid use, and
age) to the primary endpoint and the proportion of pa-




A total of 125 patients (77 from ACQUIRE and 48 from
ATTUNE) were enrolled in the pneumococcal vaccine
sub-study and received the PPSV23 vaccination. Pre-
and post-vaccination titers were available for 90.4 % of
patients (113/125), and these patients represented those
who completed the 4-week sub-study; 41.6 % of patients
(47/113) were without protective antibody levels at base-
line (Fig. 1). In the pneumococcal vaccine study, one pa-
tient had >42 days between pre- and post-vaccination
samples (57 days) and was excluded from analyses.
A total of 191 patients from the ACQUIRE study were
enrolled in the influenza vaccine sub-study and received
the influenza vaccine. Of these patients, 97.4 % (186/
191) had both pre- and post-vaccination titer samples
collected and thus completed the 4-week sub-study;
65.1 % (121/186) were without protective antibody levels
at baseline (Fig. 1). In the influenza vaccine sub-study,
two patients had >42 days between pre- and post-
vaccination samples (46 and 43 days) and were excluded
from the analyses. Baseline demographics and clinical
characteristics are shown in Tables 1 and 2.
Efficacy
Immunologic responses to vaccination
In the pneumococcal vaccine population with non-
protective antibody levels at baseline, 73.9 % of patients
mounted a response to the pneumococcal vaccine by
achieving a ≥2-fold increase in post-vaccination titers to ≥3
of 5 pneumococcal antigens assessed (Table 3). The propor-
tion of patients who mounted a response to the influenza
vaccine by achieving a ≥4-fold increase in post-vaccination
titers to ≥2 of 3 influenza antigens was 61.3 % in patients
without baseline protective antibody levels (Table 3). The
proportion of patients with a response to vaccination was
generally higher in patients without protective antibodies
compared with patients with protective antibodies at base-
line (Table 3). Overall, 55.4 % of patients in the pneumo-
coccal sub-study demonstrated protective antibody levels
(≥2-fold increase in post-vaccination titers to ≥3 of 5 anti-
gens) at 28 days post-vaccination, and 49.5 % in the influ-
enza sub-study demonstrated protective antibody levels
(≥4-fold increase in post-vaccination titers to ≥2 of 3
antigens; Table 3).
Analyses of the relationship of baseline factors to
pneumococcal or influenza vaccine response showed that
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the presence of protective antibody titers at baseline was
significantly associated with a lower likelihood of obtaining
a response to vaccination (OR: 0.3 [95 % CI: 0.1, 0.6], p =
0.0013; OR: 0.2 [95 % CI: 0.1, 0.5], p < 0.0001, respectively;
Table 4). Use of MTX, irrespective of dose, and
concomitant corticosteroid use (mean [standard deviation]
oral dose: pneumococcal, 6.8 [3.0] mg/day; influenza, 6.0
[2.6] mg/day) at sub-study baseline were not significant fac-
tors associated with response to the pneumococcal or influ-
enza vaccine (Table 4). The results for these baseline
factors (protective antibody titers, MTX dose, and steroids)
in the total population were consistent, irrespective of age
(Additional file 2: Table S2). However, baseline age on its
own was significantly associated with vaccination response
Fig. 1 Disposition of patients in the pneumococcal and influenza
vaccination sub-studies
Table 1 Baseline demographics and clinical characteristics for
the pneumococcal vaccination population
Characteristic Pneumococcal vaccine
population (N = 125)
Age
Mean (SD), years 45.7 (13.8)
Sex
Women, n (%) 107 (85.6)
Men, n (%) 18 (14.4)
Race
White, n (%) 124 (99.2)
Black/African American, n (%) 1 (0.8)
Region
South America, n (%) 105 (84.0)
North America, n (%) 20 (16.0)
Weight
Mean (SD), kg 68.9 (17.9)
Duration of abatacept exposure during main study
Mean (SD), months 26.4 (2.5)
Tender joint count/28
Mean (SD) 20.4 (16.7)
Swollen joint count/28
Mean (SD) 13.9 (11.5)
Patient pain
100-mm VAS, mean (SD) 51.0 (29.4)
HAQ-DI
Mean (SD) 1.4 (0.8)
C-reactive protein
Mean (SD), mg/dL 1.8 (2.5)
Patient global assessment
100-mm VAS, mean (SD) 43.9 (31.9)
Physician global assessment
100-mm VAS, mean (SD) 48.5 (26.3)
DAS28 (C-reactive protein)
Mean (SD) 5.0 (1.9)
Concomitant methotrexate
n (%) 115 (92.0)
DAS28 Disease Activity Score 28, HAQ-DI Health Assessment Questionnaire-
Disability Index, SD standard deviation, VAS visual analog scale
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(Table 4). Younger age (<55 years) was associated with
achieving a pneumococcal vaccine response, both in the
subgroup of patients with protective antibody levels at
baseline (OR: 2.7 [95 % CI 0.8, 8.6]) and in those without
(OR: 3.3 [95 % CI: 0.8, 14.2]). Age <55 years was also asso-
ciated with achieving an influenza vaccine response, both in
the subgroup of patients with (OR: 2.4 [95 % CI: 0.5, 12.3]
and without (OR: 3.0 [95 % CI: 1.3, 6.9]) protective antibody
levels at baseline. Similar results were observed in the total
population (OR: 2.8 [95 % CI: 1.2, 6.8], p = 0.0181; OR: 2.3
[95 % CI: 1.1, 4.7], p = 0.0211, respectively).
Post-vaccination protective antibody levels
In patients without protective pneumococcal antibody
levels at baseline, the geometric mean titers (GMTs) for
pre-vaccination pneumococcal antibodies across the five
individual antigens ranged from 0.42 to 1.29, and in-
creased to 1.69–5.17 post-vaccination; 47.5–75.5 % of
these patients achieved a ≥2-fold increase in antibody
titer to each of the five antigens compared with baseline
(Additional file 3: Table S3). In patients without protect-
ive influenza antibody levels at baseline, the pre-
vaccination influenza GMT across the three individual
Table 2 Baseline demographics and clinical characteristics for
the influenza vaccination population
Characteristic Influenza vaccine population (N = 191)
Age
Mean (SD), years 44.9 (12.6)
Sex
Women, n (%) 172 (90.1)
Men, n (%) 19 (9.9)
Race
White, n (%) 188 (98.4)
Black/African American, n (%) 2 (1.0)
Other, n (%) 1 (0.5)
Region
South America, n (%) 156 (81.7)
North America, n (%) 35 (18.3)
Weight
Mean (SD), kg 68.4 (17.3)
Duration of abatacept exposure during main study
Mean (SD), months 37.6 (2.9)
Tender joint count/28
Mean (SD) 30.7 (14.4)
Swollen joint count/28
Mean (SD) 20.3 (8.0)
Patient pain
100-mm VAS, mean (SD) 65.5 (22.2)
HAQ-DI
Mean (SD) 1.7 (0.6)
C-reactive protein,
Mean (SD), mg/dL 2.4 (2.7)
Patient global assessment
100-mm VAS, mean (SD) 64.7 (21.5)
Physician global assessment, 100-mm VAS
100-mm VAS, mean (SD) 60.3 (17.9)
DAS28 (C-reactive protein)
Mean (SD) 6.3 (0.8)
Concomitant methotrexate
n (%) 186 (97.4)
DAS28 Disease Activity Score 28, HAQ-DI Health Assessment Questionnaire-
Disability Index, SD standard deviation, VAS visual analog scale
Table 3 Immunologic responses to the pneumococcal and









n/N (%) 34/46 (73.9) 73/119 (61.3)
95 % CI 61.2, 86.6 52.6, 70.1
Patients with protective
antibody levels at baseline
n/N (%) 28/66 (42.4) 18/65 (27.7)
95 % CI 30.5, 54.3 16.8, 38.6
Total
n/N (%) 62/112 (55.4) 91/184 (49.5)





n/N (%) 16/46 (34.8) N/A
95 % CI 21.0, 48.5
Patients with protective
antibody levels at baseline
n/N (%) 8/65 (12.3) N/A
95 % CI 4.3, 20.3
Total
n/N (%) 24/111 (21.6) N/A
95 % CI 14.0, 29.3
CI confidence interval, N/A not applicable
aPrimary endpoint. Patients with >42 days between the pre- and post-
vaccination sample dates were excluded from the analysis. One patient from
the pneumococcal study had >42 days between pre- and post-vaccination
samples (57 days) and did not have protective antibody levels at baseline; the
patient did not achieve an immunologic response post-vaccination. Two patients
from the influenza study had >42 days between pre- and post-vaccination sample
(46 days: patient did not have protective antibodies at baseline and did not achieve
an immunologic response post-vaccination; 43 days: patient did not have protective
antibodies at baseline and achieved immunologic response post-vaccination)
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antigens ranged from 15.8 to 41.8, and increased to
79.7–280.9 post-vaccination. The proportion of these pa-
tients who achieved a ≥4-fold increase in antibody titer
to each of the three influenza antigens compared with
baseline ranged from 42.0 to 68.3 % (Additional file 3:
Table S3). In all patients, the pre-vaccination pneumo-
coccal or influenza GMT across the individual antigens
ranged from 1.1 to 3.7 and from 27.8 to 83.7, respect-
ively, and increased to 2.9–9.7 or 99.0–296.1 post-
vaccination (Additional file 4: Table S4). Immunologic
responses for the total populations ranged from 43.8 to
57.1 % with the pneumococcal vaccination and from
35.3 to 54.9 % with the influenza vaccination (Additional
file 4: Table S4).
A high proportion of patients without protective anti-
body levels at baseline achieved protective antibody levels
to ≥3 of 5 pneumococcal vaccine antigens (65.2 %) or ≥2
of 3 influenza vaccine antigens (73.1 %). In the total
pneumococcal vaccination population, 83.9 % of patients
demonstrated protective levels (antibody titer ≥1.6 μg/mL)
to ≥3 of 5 antigens assessed post-vaccination (Additional
file 5: Table S5). In the total influenza vaccination
Table 4 Relationship of baseline factors with pneumococcal and influenza immunologic responses
Baseline characteristic Pneumococcal vaccine Influenza vaccine
n/N (%) OR (95 % CI) n/N (%) OR (95 % CI)
Patients without protective antibody levels at baselinea
MTX dose at baseline, mg/week None 2/4 (50.0) 0.3 (0.0, 3.0) 1/3 (33.3) 0.4 (0.0, 4.5)
>0–10 5/7 (71.4) 0.6 (0.1, 6.0) 17/25 (68.0) 1.6 (0.5, 4.7)
>10–15 19/25 (76.0) 0.8 (0.1, 4.8) 35/36 (62.5) 1.3 (0.5, 3.0)
>15 8/10 (80.0) 20/35 (57.1)
Steroid at baseline Yes 19/26 (73.1) 0.9 (0.2, 3.4) 47/74 (63.5) 1.3 (0.6, 2.7)
No 15/20 (75.0) 26/45 (57.8)
Age at main study baseline, years <55 28/35 (80.0) 3.3 (0.8, 14.2) 60/88 (68.2) 3.0 (1.3, 6.9)
≥55 6/11 (54.5) 13/31 (41.9)
Patients with protective antibody levels at baselinea
MTX dose at baseline, mg/week None 2/6 (33.3) 0.6 (0.1, 4.1) 3/5 (60.0) 3.6 (0.5, 26.8)
>0–10 8/15 (53.3) 1.4 (0.4, 5.4) 3/12 (25.0) 0.8 (0.2, 3.9)
>10–15 9/25 (36.0) 0.7 (0.2, 2.3) 5/24 (20.8) 0.6 (0.2, 2.4)
>15 9/20 (45.0) 7/24 (29.2)
Steroid at baseline Yes 16/37 (43.2) 1.1 (0.4, 2.9) 10/40 (25.0) 0.7 (0.2, 2.1)
No 12/29 (41.4) 8/25 (32.0)
Age at main study baseline, years <55 23/47 (48.9) 2.7 (0.8, 8.6) 16/52 (30.8) 2.4 (0.5, 12.3)
≥55 5/19 (26.3) 2/13 (15.4)
Total populationb
Protective antibody level at baseline Yes 28/66 (42.4) * 0.3 (0.1, 0.6) 18/65 (27.7) ** 0.2 (0.1, 0.5)
No 34/46 (73.9) * 73/119 (61.3) **
MTX dose at baseline, mg/week None 4/10 (40.0) 0.5 (0.1, 2.2) 4/8 (50.0) 1.2 (0.3, 5.2)
>0–10 13/22 (59.1) 1.1 (0.4, 3.4) 20/37 (54.1) 1.4 (0.6, 3.2)
>10–15 28/50 (56.0) 1.0 (0.4, 2.4) 40/80 (50.0) 1.2 (0.6, 2.3)
>15 17/30 (56.7) 27/59 (45.8)
Steroid at baseline Yes 35/63 (55.6) 1.0 (0.5, 2.2) 57/114 (50.0) 1.1 (0.6, 1.9)
No 27/49 (55.1) 34/70 (48.6)
Age at main study baseline, years <55 51/82 (62.2) 2.8 (1.2, 6.8) *** 76/140 (54.3) 2.3 (1.1, 4.7) ***
≥55 11/30 (36.7) 15/44 (34.1)
Based on the total population, regardless of protective antibody status at baseline. ORs and 95 % likelihood ratio CIs are based on a logistic regression model:
vaccine response = baseline factor. ORs and CIs are presented for each category versus the reference category (baseline protective [no], MTX >15 mg/week,
steroid [no], age ≥55 years). P-values are for confounding factors. Patients with >42 days between the pre- and post-vaccination sample dates were excluded from
the analysis
CI confidence interval, MTX methotrexate, OR odds ratio
aMultivariate model; bbivariate model; *p = 0.0013; **p < 0.0001; ***p < 0.05
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population, 82.1 % of patients achieved protective levels
(antibody titer ≥1:40) to ≥2 of 3 antigens post-vaccination
(Additional file 5: Table S5).
The impact of concomitant MTX and steroid use on
achieving post-vaccination protective antibody levels is
shown in Additional file 6: Table S6. In both sub-studies,
a high percentage of patients achieved protective anti-
body levels post-vaccination, regardless of baseline con-
comitant medication use.
Safety
Overall, 15/125 (12.0 %) and 27/191 patients (14.1 %)
reported AEs with the pneumococcal and influenza vac-
cine, respectively. One of the AEs reported in the pneumo-
coccal vaccine study was a sore left arm (1/125 [0.8 %])
and was reported as mild in intensity; this was considered
by the investigator to be unrelated to the pneumococcal
vaccine. Overall, infections were reported in 7 patients
(5.6 %): nasopharyngitis (n = 6; 4.8 %) and urinary tract in-
fection (n = 1; 0.8 %). All infections were of mild intensity,
with the exception of one event of moderate intensity
(nasopharyngitis). In the influenza sub-study there was one
SAE reported (1/191 [0.5 %]); a 71-year-old woman experi-
enced severe chest pain that began after vaccination on
Day 18 of the vaccine sub-study. The chest pain was
treated and resolved within 3 days. There was no action
taken with the study drug and, in the opinion of the inves-
tigator, the event was unlikely to be related to the study
drug. Overall, nine patients (4.7 %) had an infection in the
influenza sub-study. Infections reported for more than one
patient included nasopharyngitis (n = 4; 2.1 %) and upper
respiratory tract infection (n = 2; 1.0 %). There were no
deaths or discontinuations owing to AEs in either sub-
study.
Discussion
The efficacy of the pneumococcal and influenza vaccines
given during SC abatacept therapy was consistent with
previous reports for IV abatacept; specifically, patients
were still able to mount an immune response when on
abatacept [18–20]. In the present two sub-studies of pa-
tients with RA receiving abatacept and background
DMARDs, the majority of vaccinated patients without
protective antibody levels at baseline achieved an im-
mune response to the standard PPSV23 and influenza
virus vaccines. Despite the absence of a control group of
vaccinated patients who were not receiving abatacept,
nor larger numbers of vaccinated patients receiving aba-
tacept who did not also receive MTX, the level of re-
sponse in these two vaccination sub-studies suggests
that abatacept does not interfere significantly with T-cell
presentation and sensitization of an antigen given as a
vaccine. The proportion of patients with an overall re-
sponse to vaccination was lower in patients who had
protective antibody levels at baseline compared with pa-
tients who did not, indicating that the booster responses
were of smaller magnitude than the primary vaccination
responses in these sub-studies. Consistent with this ob-
servation, analyses of baseline factors with vaccine
response showed protective antibody titers at baseline to
be a significant factor impacting vaccine response.
SC abatacept demonstrated no new safety signals fol-
lowing vaccinations, and pneumococcal and influenza
vaccinations during SC abatacept administration were
well tolerated. The safety profile of SC abatacept follow-
ing vaccinations was consistent with previous reports for
IV abatacept [18, 20]. Additionally, vaccination with the
PPSV23 and influenza vaccines was well tolerated by pa-
tients with RA treated with abatacept, and these results
are consistent with other vaccination studies in patients
receiving biologic therapies, specifically rituximab, adali-
mumab, and tocilizumab [1, 26, 27, 30, 35].
Although the US Food and Drug Administration pro-
vides guidelines for influenza vaccination studies [34] and
van Assen et al. [6] have reported recommendations from
the European League Against Rheumatism for vaccina-
tions in adults with autoimmune inflammatory rheumatic
diseases, there are currently no specific guidelines for vac-
cination studies in patients with RA treated with biologics
[1]. Across various vaccination studies in patients with RA
that were included in a systematic analysis, there was
some variability in reporting immunologic responses, in-
cluding measures of GMT, seroresponse (immunologic re-
sponse), seroprotection (protective antibody levels), and
seroconversion (Additional file 1: Table S1) [1]. Whereas
definitions of an immunologic response and protective
antibody levels for influenza were relatively consistent
across these studies [1, 30, 31, 34], controversy remains
regarding the definition of protective antibody levels for
each pneumococcal serotype [23]. An immunologic re-
sponse to the PPSV23 in patients with RA has been de-
fined as a ≥2-fold increase in post-vaccination titers to ≥3
of 5 antigens (9V, 14, 18C, 19F, and 23F) [18, 29, 30, 32].
In two RA vaccination studies, the protective antibody
level for pneumococcal serotypes has been reported as a
titer of 1.6 μg/mL [25, 30, 31]. In several other studies, the
consensus value has been reported as 1.3 μg/mL [25], but
studies have used a value as low as 1.0 μg/mL [1, 25–27]
or as high as 2.0 μg/mL [1, 25, 36–38]. The use of differ-
ent vaccination response definitions across studies in pa-
tients with RA presents a challenge to clinicians who are
making biologic treatment decisions.
In addition to the definition of response, the use of
concomitant medications (MTX and/or prednisone) is
another factor that might impact the results of immuno-
logic response; in particular, MTX has been shown to
affect pneumococcal vaccination response in a dose-
dependent manner [39]. However, in the present
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pneumococcal and influenza vaccination sub-studies,
there was no significant impact of concomitant use of
MTX, irrespective of dose, or of concomitant corticoste-
roids on the proportion of patients achieving protective
antibody levels in patients treated with abatacept.
Age can also be a factor that influences immunologic re-
sponses to vaccines [40–42]. Elderly individuals (>65 years)
might have greater difficulty mounting a protective re-
sponse to influenza and pneumococcal vaccines compared
with younger adults [40–43]. In the present studies, higher
proportions of patients aged <55 years achieved responses
to pneumococcal or influenza vaccination.
As a result of the predefined exclusion criteria, which
stated that patients with >42 days between the pre- and
post-vaccination sample dates were excluded from all ana-
lyses, data from three patients were not analyzed: one pa-
tient from the pneumococcal vaccine sub-study and two
from the influenza vaccine sub-study. The patient excluded
from the pneumococcal vaccine study did not have protect-
ive antibody levels at baseline and did not achieve an im-
munologic response post-vaccination; it is unlikely that
results from this patient would have greatly impacted the
overall results. Of the two patients excluded from the influ-
enza vaccine sub-study, one did not have protective anti-
bodies at baseline and did not achieve an immunologic
response post-vaccination, while the other did not have
protective antibodies at baseline and achieved an immuno-
logic response post-vaccination. As a consequence, the ex-
cluded results for influenza vaccination may have cancelled
each other out and therefore would not have greatly af-
fected the overall results.
There are several limitations to these sub-studies. The
RA population in these sub-studies consisted of patients
who were receiving abatacept; therefore, there were no pa-
tients with RA who were not receiving abatacept as a con-
trol group for comparison. ATTUNE comprised a single
SC abatacept 125-mg/week treatment arm; ACQUIRE
comprised an SC abatacept 125-mg/week treatment arm
and an IV abatacept weight-tiered dose treatment arm (not
analyzed here). In addition, almost all patients also received
concomitant MTX (with the exception of 10 and 5 patients
for the pneumococcal and influenza vaccine studies, re-
spectively). Although there was no control group of pla-
cebo/MTX for direct comparison, overall immune
response levels in this study were on a par with those from
controlled studies that have used similar definitions for
vaccine response [30, 31]. Also, due to the lack of a control
group, we were unable to evaluate the effects of abatacept
on the immunogenicity of PPSV23 by comparing patients
with RA treated with abatacept versus placebo/MTX.
Functional antibody activity as measured by opsonophago-
cytosis was also not investigated. With regard to the
pneumococcal vaccine assessed, the analyses in this vaccin-
ation sub-study did not determine responses to the
pneumococcal conjugate vaccine (13-valent pneumococcal
conjugate vaccine [PCV13]) or to the sequence of
pneumococcal vaccines (PPSV23 and PCV13 separated by
time) recently recommended by the Advisory Committee
on Immunization Practices/Centers for Disease Control
and Prevention [44]. Additionally, for the pneumococcal
vaccination analysis, response to the five antigens utilized
in this and other vaccination studies does not guarantee re-
sponse to the remaining antigens in the PPSV23 [29].
Given the different patient populations included, caution
should be used when drawing comparisons from the AC-
QUIRE (pneumococcal and influenza vaccine) and AT-
TUNE (pneumococcal vaccine) sub-studies.
Conclusions
These data suggest that the majority of patients with RA
receiving SC abatacept treatment are able to mount an
appropriate primary or booster immune response to ei-
ther the pneumococcal or the influenza vaccine. Further-
more, immunizations with pneumococcal polysaccharide
and inactivated influenza vaccines have a good safety
profile in abatacept-treated patients. Achieving optimal
responses may require vaccination before initiating aba-
tacept, if feasible; however, patients should continue to
receive primary, booster, or annual vaccines.
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